China Biologics Contract Development Market Size & Outlook
China biologics contract development market, 2018-2030 (US$M)
Related Markets
China biologics contract development market highlights
- The China biologics contract development market generated a revenue of USD 373.6 million in 2023 and is expected to reach USD 811.1 million by 2030.
- The China market is expected to grow at a CAGR of 11.7% from 2024 to 2030.
- In terms of segment, mammalian source was the largest revenue generating source in 2023.
- Mammalian Source is the most lucrative source segment registering the fastest growth during the forecast period.
Biologics contract development market data book summary
| Market revenue in 2023 | USD 373.6 million |
| Market revenue in 2030 | USD 811.1 million |
| Growth rate | 11.7% (CAGR from 2023 to 2030) |
| Largest segment | Mammalian source |
| Fastest growing segment | Mammalian Source |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Microbial Source, Mammalian Source, Other Source |
| Key market players worldwide | WuXi Biologics (Cayman) Inc, FUJIFILM Holdings Corp, AGC Biologics, Thermo Fisher Scientific Inc, Curia, Genscript Biotech Corp Class H, Boehringer Ingelheim Pharma, Abzena, JSR Corp, Bionova Scientific |
Other key industry trends
- In terms of revenue, China accounted for 4.7% of the global biologics contract development market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China biologics contract development market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 811.1 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Biologics Contract Development Market Scope
Biologics Contract Development Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
China biologics contract development market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biologics contract development market will help companies and investors design strategic landscapes.
Mammalian source was the largest segment with a revenue share of 53.77% in 2023. Horizon Databook has segmented the China biologics contract development market based on microbial source, mammalian source, other source covering the revenue growth of each sub-segment from 2018 to 2030.
China is a lucrative market owing to favorable government initiatives regulating clinical trials as per global standards and well-developed infrastructure, which includes 4,000 hospital beds.
Initially, in China, CRFA was responsible for regulating clinical trials; however, realizing the potential of CRO market and the need for regulating clinical trials as per global standards, the National Medical.
In April 2020, WuXi Biologics announced completion of an acquisition deal with Bayer for a drug product manufacturing plant in Leverkusen, Germany. This facility has state-of-the-art drug product filling line, sterile filling, and freeze drying services of up to 10 million vials per year, and WuXi Biologics has taken over the plant operations.
Reasons to subscribe to China biologics contract development market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of China biologics contract development market databook
-
Our clientele includes a mix of biologics contract development market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China biologics contract development market, including forecasts for subscribers. This country databook contains high-level insights into China biologics contract development market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
China biologics contract development market size, by source, 2018-2030 (US$M)
China Biologics Contract Development Market Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
